Alex Dumortier, CFA

You can listen to JPMorgan Chase CEO Jamie Dimon when it comes to the business of banking, but take his views on banking regulation with a whale-sized pinch of salt.

Pfizer shareholders must evaluate the collapse of the Pfizer-Allergan deal with regard to the tenure of CEO Ian Read.

The first quarter was an unmitigated disaster for active fund managers, and the long-term performance numbers tell the same story.

The S&P 500's dividends per share have declined quarter over quarter for the first time in two years.

European banks were the worst-performing asset class in the first quarter. That's a good reason to take a look at them.

Gold and equities exhibited reversals in their price momentum in the first quarter, proving that focusing on short-term performance is futile.

The VIX Volatility Index falls to a new low for 2016; meanwhile, labor scores a victory over capital -- is it the start of a broad trend?

Associations with prestigious organizations or figures are nice, but the stories of Valeant Pharmaceuticals International and Theranos prove they aren't enough -- investors must dig deeper.

Wells Fargo has been one of Warren Buffett's best stock picks on behalf of Berkshire Hathaway, but UBS doesn't think his stock-picking ability is required for Berkshire to outperform.

Bob Goldfarb of Ruane, Cunniff & Goldfarb -- a company once linked to Warren Buffett -- steps down as the Valeant Pharmaceuticals debacle rolls on.

Keefe, Bruyette & Woods calls for a breakup of Citigroup Inc., and the numbers justify it.

The gap between companies' adjusted earnings and earnings based on GAAP is at a worrying level.

Financial data provider Markit is merging with IHS; meanwhile, Valeant Pharmaceuticals International turns over a new leaf.

The "fear trade" in gold has been a winner; Bank of America ups its buyback authorization.

Over the long term, most mutual funds fail to deliver on their mandate to beat their benchmark index.

The global steel market is a long way from a recovery, and that means steel producers have a big incentive to get bigger.

Oil and gas shares and oil prices don't bottom simultaneously; the recent rally in the price of oil may be premature.

The beverage colossus faces a stiff secular headwind as consumers and public authorities are increasingly concerned about the health effects of sugary soft drinks.

Valeant Pharmaceuticals takes another activist investor onboard, and Google parent Alphabet records a historic milestone for its push into artificial intelligence.

As the U.S. economy diverges from those of Japan and the eurozone, negative interest rates reveal a dark side.